Novo Nordisk expands access to weight-loss drug Wegovy through telehealth partnerships, offering discounted rates as compounded alternatives become less available.
First Solar cuts 2025 outlook after Q1 earnings miss, citing new tariffs and market pressures, but remains optimistic about long-term growth prospects.
Novo Nordisk expands access to weight-loss drug Wegovy through telehealth partnerships, offering discounted rates as compounded alternatives become less available.
First Solar cuts 2025 outlook after Q1 earnings miss, citing new tariffs and market pressures, but remains optimistic about long-term growth prospects.